Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder.<ref name=":9"></ref> Symptoms include hematuria, dysuria, and low back pain.<ref name=":9" />
Risk factors for bladder cancer include smoking, family history, prior radiation therapy, frequent bladder infections, and exposure to certain chemicals.<ref name=":9" /> The most common type is transitional cell carcinoma.<ref name=":9" /> Other types include squamous cell carcinoma and adenocarcinoma.<ref name=":9" /> Diagnosis is typically by cystoscopy with tissue biopsy.<ref name=NCI2017Pro></ref> Staging of the cancer is determined by transurethral resection and medical imaging.<ref name=":9" /><ref></ref><ref></ref>
Treatment depends on the cancer stage.<ref name=":9" /> It may include some combination of surgery, radiation therapy, chemotherapy, or immunotherapy.<ref name=":9" /> Surgical options may include transurethral resection, partial or complete removal of the bladder, or urinary diversion.<ref name=":9" /> The typical five-year survival rates in the United States is 77%, Canada is 75%, and Europe is 68%.<ref name=SEER2019/><ref></ref><ref></ref>
 
Bladder cancer, as of 2018, affected about 1.6 million people globally with 549,000 new cases and 200,000 deaths.<ref name = Global2018></ref> Age of onset is most often between 65 and 84 years of age.<ref name=SEER2019></ref> Males are more often affected than females.<ref name=SEER2019/> In 2018, the highest rate of bladder cancer occurred in Southern and Western Europe followed by North America with rates of 15, 13, and 12 cases per 100,000 people.<ref name = Global2018/> The highest rates of bladder cancer deaths were seen in Northern Africa and Western Asia followed by Southern Europe.<ref name = Global2018/>